Cargando…

DAPA-CKD: The Beginning of a New Era in Renal Protection

Detalles Bibliográficos
Autores principales:	Cherney, David Z.I., Verma, Subodh
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Elsevier 2021
Materias:	Translational Perspective
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7838045/ https://www.ncbi.nlm.nih.gov/pubmed/33532667 http://dx.doi.org/10.1016/j.jacbts.2020.10.005

Ejemplares similares

The dapagliflozin and prevention of adverse outcomes in chronic kidney disease (DAPA-CKD) trial: baseline characteristics
por: Wheeler, David C, et al.
Publicado: (2020)

Extrapolated longer-term effects of the DAPA-CKD trial: a modelling analysis
por: McEwan, Phil, et al.
Publicado: (2022)

Dapagliflozin, advanced chronic kidney disease, and mortality: new insights from the DAPA-CKD trial
por: Marx, Nikolaus, et al.
Publicado: (2021)

Effect of dapagliflozin on kidney and cardiovascular outcomes by baseline KDIGO risk categories: a post hoc analysis of the DAPA-CKD trial
por: Waijer, Simke W., et al.
Publicado: (2022)

Efficacy of Dapagliflozin by Baseline Diabetes Medications: A Prespecified Analysis From the DAPA-CKD Study
por: Beernink, Jelle M., et al.
Publicado: (2023)

Effects of Dapagliflozin in Chronic Kidney Disease, With and Without Other Cardiovascular Medications: DAPA‐CKD Trial
por: Chertow, Glenn M., et al.
Publicado: (2023)

Efficacy and Safety of Dapagliflozin by Baseline Glycemic Status: A Prespecified Analysis From the DAPA-CKD Trial
por: Persson, Frederik, et al.
Publicado: (2021)

Preventing CKD in Developed Countries
por: Luyckx, Valerie A., et al.
Publicado: (2019)

Soluble fms-Like Tyrosine Kinase 1 Localization in Renal Biopsies of CKD
por: Zsengellér, Zsuzsanna K., et al.
Publicado: (2019)

Rationale and protocol of the Dapagliflozin And Prevention of Adverse outcomes in Chronic Kidney Disease (DAPA-CKD) randomized controlled trial
por: Heerspink, Hiddo J L, et al.
Publicado: (2020)

Clinical Outcomes and Healthcare Resource Utilization in a Real-World Population Reflecting the DAPA-CKD Trial Participants
por: Olufade, Tope, et al.
Publicado: (2021)

Commentary: Renal Nerve Denervation: Is Renervation an Issue?
por: Rothstein, Marcos
Publicado: (2016)

A Perspective on the Delivery of Renal Denervation Therapy Based on Pre-Clinical Data
por: Tellez, Armando, et al.
Publicado: (2016)

ACLY and CKD: A Mendelian Randomization Analysis
por: Mohammadi-Shemirani, Pedrum, et al.
Publicado: (2022)

The beginning of a new era…
por: Hassan, Ali H.
Publicado: (2012)

Effects of dapagliflozin on mortality in patients with chronic kidney disease: a pre-specified analysis from the DAPA-CKD randomized controlled trial
por: Heerspink, Hiddo J L, et al.
Publicado: (2021)

Effects of dapagliflozin in DAPA-HF according to background heart failure therapy
por: Docherty, Kieran F, et al.
Publicado: (2020)

Prescribing SGLT2 Inhibitors in Patients With CKD: Expanding Indications and Practical Considerations
por: Yau, Kevin, et al.
Publicado: (2022)

Prescribing SGLT2 Inhibitors in Patients With CKD: Expanding Indications and Practical Considerations
por: Yau, Kevin, et al.
Publicado: (2022)

Efficacy of Dapagliflozin on Renal Function and Outcomes in Patients With Heart Failure With Reduced Ejection Fraction: Results of DAPA-HF
por: Jhund, Pardeep S., et al.
Publicado: (2020)

Iron Deficiency in Heart Failure and Effect of Dapagliflozin: Findings From DAPA-HF
por: Docherty, Kieran F., et al.
Publicado: (2022)

Interleukin-6 Contributes to the Development of Anemia in Juvenile CKD
por: Akchurin, Oleh, et al.
Publicado: (2018)

Beginning a new medical school curriculum amidst a global pandemic
por: Shah, Nirav G., et al.
Publicado: (2020)

C-Type Natriuretic Peptide in Essential Hypertension: Old Ways for a New Time
por: Perunovic, Tara, et al.
Publicado: (2023)

Location-Specific Oral Microbiome Possesses Features Associated With CKD
por: Hu, Jianzhong, et al.
Publicado: (2017)

Advances of mRNA vaccines for COVID-19: A new prophylactic revolution begins
por: Weng, Yuhua, et al.
Publicado: (2021)

A Functional Landscape of CKD Entities From Public Transcriptomic Data
por: Tajti, Ferenc, et al.
Publicado: (2019)

Less is more: Antibiotics at the beginning of life
por: Stocker, Martin, et al.
Publicado: (2023)

Effects of Dapagliflozin in Asian Patients With Heart Failure and Reduced Ejection Fraction in DAPA-HF
por: Docherty, Kieran F., et al.
Publicado: (2022)

Ethical and Clinical Considerations During the Coronavirus Era
por: McGee, Maria E., et al.
Publicado: (2021)

Early Ultrastructural Changes in Biopsies From Patients With Symptomatic CKD of Uncertain Etiology
por: Daniel, Christoph, et al.
Publicado: (2022)

Targeting Vascular Calcification in CKD: Time to Redraw the Map
por: O'Neill, W. Charles
Publicado: (2023)

Safety and efficacy of dapagliflozin in patients with focal segmental glomerulosclerosis: a prespecified analysis of the dapagliflozin and prevention of adverse outcomes in chronic kidney disease (DAPA-CKD) trial
por: Wheeler, David C, et al.
Publicado: (2021)

2021: the beginning of a new era of immunisations?
por: The Lancet
Publicado: (2021)

Dapagliflozin and Diuretic Use in Patients With Heart Failure and Reduced Ejection Fraction in DAPA-HF
por: Jackson, Alice M., et al.
Publicado: (2020)

The CNP/NPR-B/cGMP Axis is a Therapeutic Target in Calcific Aortic Stenosis
por: Armstrong, David W.J., et al.
Publicado: (2021)

What is paradoxical lucidity? The answer begins with its definition
por: Peterson, Andrew, et al.
Publicado: (2021)

The Hospital Antimicrobial Use Process: From Beginning to End
por: Truong, William R, et al.
Publicado: (2018)

Mobile health: new technologies, new modes and new era
por: Zhao, Gang, et al.
Publicado: (2016)

Metabolic Strategies in Healthcare: A New Era
por: Phillips, Matthew CL
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_rgbm39b64seeh4hqkk1po3s15j